VIZAMYL (flutemetamol, 18F), diagnostic product for the central nervous system
DIAGNOSIS - New medicinal product
Opinions on drugs -
Posted on
May 11 2017
Reason for request
Inclusion
- VIZAMYL is a radiopharmaceutical with marketing authorisation for positron emission tomography (PET) imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease or other causes of cognitive impairment.
- Based on poor diagnostic performance and the lack of any proven advantage over the diagnostic tools already available, particularly in situations where differential diagnosis is difficult, VIZAMYL has no role as a diagnostic test for cognitive impairment.
Clinical Benefit
Insufficient |
- |
Clinical Added Value
Not applicable |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments